TP53 and prostate cancer: Initially, we utilized mouse prostate cancer organoids [22], and the findings demonstrated that knockdown of mouse YTHDF1 (mYTHDF1) markedly reduced the clonogenic formation of Pten- or/and TP53-deficient organoids (Figs. 2J–M, S2C–D).